ALZ-801
4 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.
Trials
4
Ongoing
0
Recruiting
0
Completed
3
Sites
102
Countries
9
Endpoints
104
Composite endpoints
0
Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 104 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Normalized metric codes are available for 29 of 104 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.
8
8
8
1
1
1
1
1
Trials
Trials for this asset
Every trial for this asset, with the same search, filters, and sort as the Trials tab.
4 of 4
| Asset / Disease area | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| APOLLOE4An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects | ALZ-801 Alzheimer’s disease | Alzheimer's disease | Ph 3 | Completed | 95 | May 2024 | 1 | results |
| APOLLOE4-LTELong-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects | ALZ-801 Alzheimer’s disease | Study partner/caregiver required | Ph 3 | Terminated | 41 | Mar 2026 | - | |
| NCT04693520Biomarker Effects of ALZ-801 in APOE4 Carriers With Early Alzheimer's Disease | ALZ-801 Alzheimer’s disease | Alzheimer's disease | Ph 2 | Completed | 6 | Jun 2023 | 3 | |
| NCT04585347Single Dose Study of ALZ-801 Prototype Tablets | ALZ-801 Alzheimer’s disease | Age 18-65 | Ph 1 | Completed | 0 | Nov 2015 | 1 |
Showing 1-4 of 4 trials